Nosocomial Fungemia in a Large Community Teaching Hospital

Report of ESGNI–001 and ESGNI–002 studies. Bloodstream infections in Europe

“…It amounted to 8% of all episodes of significant bloodstream infections in the SCOPE Program in the USA [32]. At the same time, many institutions reported a shift to non‐albicans species which now represent at least 50% of the isolates in many reports [24–26,29]. In our study, 4.6% of overall isolates belonged to the genus Candida , but only 7 out of 14 were C. albicans.…”

“…Regarding fungemia, Candida is the etiologic agent in the vast majority of episodes. In recent years, an increasing trend in the incidence of episodes of candidemia has been reported [24–32]. It amounted to 8% of all episodes of significant bloodstream infections in the SCOPE Program in the USA [32].…”

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy

“…In another study of candidemia in ICU patients, the clinical response rate was higher in patients treated with 10 mg/kg per day than in patients treated with 5 mg/kg per day [26]. In some studies, antifungal therapy improved the mortality rate [33][34][35], while in others [2,36] antifungal therapy had no effect on outcome. However, in a study by our group [23], 6 non-neutropenic critically ill patients received a mean dose of 200 mg for 20 days and all were cured.…”

Is Candida albicans a cause of nosocomial infection in Iran?

“…In the mid-1980s, many institutions, including cancer research, university and community hospitals, reported that fungi were becoming common pathogens in nosocomial infections [12,13]. In addition, during 1980-1990, hospitals reporting data as part of the NNIS system reported a steady increase in the rate of nosocomial fungal infections, from 2.0 to 3.8 per 1000 discharges [4].…”